trends in
PHARMACOLOGICAL SCIENCES
including TOXICOLOGICAL SCIENCES

Author Index

Subject Index

Books Reviewed Index

1996

Vol 17
Issues 1–12

ISSN 0165 6147

ELSEVIER
TRENDS
JOURNALS

Trends in Pharmacological Sciences

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410
E-mail: TIPS@elsevier.co.uk

Advisory Editorial Board

P. M. Beart, Monash University, Melbourne, Australia
N. J. M. Birdall, National Institute of Medical Research, London, UK
N. G. Bowery, University of Birmingham, Birmingham, UK
J. N. Crawley, National Institute of Mental Health, Bethesda, MD, USA
A. C. Cuello, McGill University, Montréal, Canada
J. R. Fozard, Sandoz, Basel, Switzerland
B. B. Fredholm, Karolinska Institute, Stockholm, Sweden
T. Godfraind, Université Catholique de Louvain, Brussels, Belgium
M. Lazdunski, Université de Nice, Valbonne, France
P. Leff, Astra, Loughborough, UK
L. Limbird, Vanderbilt University, Nashville, TN, USA
J. Meldolesi, Instituto H. San Raffaele, Milan, Italy
M. Otsuka, Tokyo Medical & Dental University, Tokyo, Japan
C. P. Page, King's College, London, UK
U. Quast, University of Tübingen, Germany
M. M. Reidenberg, Cornell Medical Center, New York, NY, USA
R. Ruffolo, Jr, SmithKline Beecham, King of Prussia, PA, USA
C. D. Strader, Schering-Plough Research Institute, Kenilworth, NJ, USA
H. Timmerman, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Z. G. Wang, Institute of Basic Medical Sciences, Beijing, China

Editor **Deborah Girdlestone**

Assistant Editors **Ian K. Wright and Annette Mead**

Editorial Administrator **Claire Robson**

Publisher **Peter Desmond**

Copyright © 1997 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Author Index

BR Book Review
L Letter
SR Software Review

A

Alexander, S. P. and Ford, A. P. D. W., Purines '96 385
Anderson, G. P., Resolution of chronic inflammation by therapeutic induction of apoptosis 438
Argilés, J. M. and López-Soriano, F. J., The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states 223
Arner, P., *see* Lafontan, M. 309
Arribas, S., *see* McGrath, J. C. 393
Ashton, C. H., *see* Young, A. H. (L) 400
Awobuluyi, M., *see* Sucher, N. J. 348

B

Balla, T., *see* Hunyady, L. 135
Barnard, E. A., The transmitter-gated channels: a range of receptor types and structures 305
Barnes, N. M., *see* Parker, R. M. C. 95
Bayne, M. L., *see* Murgolo, N. J. 389
Beani, L., *see* Simonato, M. 410
Beart, J. J., *see* Reid, P. M. 205
Behan, D. P., *see* Chalmers, D. T. 166
Ben-Ari, Y., *see* Gozlan, H. (L) 187
Bentley, K. R., *see* Parker, R. M. C. 95
Bertrand, C. and Geppetti, P., Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease 255
Birdsall, N., *see* Lazareno, S. (L) 443
Black, J. W., *TiPS* on identity 121
Bolard, J., *see* Hartsel, S. C. 445
Bond, R. A. and Girdlestone, D., Romancing receptor research at Verona classification meeting 85
Boutin, J. A. and Fauchere, A. L., Combinatorial peptide synthesis: statistical evaluation of peptide distribution 8
Bowery, N. G., *see* Malcangio, M. 457
Brink, C., *see* Gorenne, I. 342
Brotchie, J. M., *see* Fox, S. H. 339
Brown, J. E., *see* Murgolo, N. J. 389
Bruns, R. F., Conformational induction versus conformational selection: evidence from allosteric enhancers (L) 189
Buckel, P., Recombinant proteins for therapy 450

C

Candura, S. M., *see* Tonini, M. (L) 314
Catt, K. J., *see* Hunyady, L. 135
Chalmers, D. T., Lovenberg, T. W., Grigoriadis, D. E., Behan, D. P. and de Souza, E. B., Corticotrophin-releasing factor receptors: from molecular cloning to drug design 166
Chapman, I. D., Contract research pharmacology 60
Choi, Y-B., *see* Sucher, N. J. 348
Choi, Y-B., *see* Lipton, S. A. (L) 186
Christopher, N., *see* Ferguson, D. (L) 315
Christopher, N., *see* Ferguson, D. 161
Chuang, T. T., Iacovelli, L., Sallese, M. and De Blasi, A., G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications 416
Coleman, R. A., Johnson, M., Nials, A. T. and Vardey, C. J., Exosites: their current status, and their relevance to the duration of action of long-acting β_2-adrenoceptor agonists 324
Connolly, G. P., Simmonds, H. A. and Duley, J. A., Pyrimidines and CNS regulation (L) 106
Cooper, D. M. F., *Signal Transduction Protocols* (BR) 201
Corsi, M., Fina, P. and Trist, D. G., Co-agonism in drug–receptor interaction: illustrated by the NMDA receptors 220
Costa, E. and Guidotti, A., Benzodiazepines on trial: a research strategy for their rehabilitation 192
Cox, H. M., *see* Playford, R. J. 436
Cusack, B., *see* Le, F. 1

D

Daly, C. J., *see* McGrath, J. C. 393
Daly, J. W., *see* Jacobson, K. A. 108
Darlington, C. L., *see* Smith, P. F. 421
Davies, H. J., *A Guide to Clinical Drug Research* (BR) 463
Davis, T. P., *see* Konkoy, C. S. 288
De Blasi, A., *see* Chuang, T. T. 416
de Souza, E. B., *see* Chalmers, D. T. 166
Demolombe, S., *see* Escande, D. 273
Devlin, J. M., Pharmacology education in the USA: I. The role of undergraduate programmes 40
Duley, J. A., *see* Connolly, G. P. (L) 106

E

Elbadawi, A., *see* Kuchel, G. A. (L) 314
Elliot, J. D., *see* Warner, T. D. 177
Elmhirst, D. N., Working fom home: freelance medical writing 64
Engebrecht, J., *see* Morris, A. J. 182
Engels, P., *see* Müller, T. 294
Escande, D. and Demolombe, S., ATP-binding cassette proteins as targets for drug discovery 273
Esposito, E., An indirect action for fluoxetine on the dopamine neurotransmitter system (L) 400

F

Fauchere, A. L., *see* Boutin, J. A. 8
Ferguson, D. and Christopher, N., Ferguson and Christopher reply (L) 315
Ferguson, D. and Christopher, N., Urinary bladder function and drug development 161
Fernandez-Salguero, P., *see* McLeod, H. L. (L) 107
Feuerstein, G., *see* Wang, X. 276
Fina, P., *see* Corsi, M. 220
Flower, R. J. *et al.*, The William Harvey Research Institute: 10th anniversary 271
Ford, A. P. D. W., *see* Alexander, S. P. 385
Fox, S. H. and Brotchie, J. M., New treatments for movement disorders? 339
Fozard, J. R., *see* Müller, T. 294
Fredholm, B. B., *see* Ongini, E. 364
Fredholm, B. B., *see* Jacobson, K. A. 108
Freeman, J., Careers in pharmaceutical clinical development 63
Frohman, M. A., *see* Morris, A. J. 182
Frölich, J. C., Careers in pharmacology: the German perspective 47

G

Gargalidis Moudanos, C., *see* Parini, A. 13
George, C. F. and Paterson, J. W., Festschrift in honour of Professor Sir Colin Dollery 317
Geppetti, P., *see* Bertrand, C. 255
Giembycz, M. A., Phosphodiesterase 4 and tolerance to β_2-adrenoceptor agonists in asthma 331
Girdlestone, D., *Emerging Drugs* (BR) 337
Girdlestone, D., *TiPS* Advisory Editorial Board 7
Girdlestone, D. and Page, C. P., What to do with a degree in pharmacology? 31
Girdlestone, D., Educational and industrial contacts in the UK 82
Girdlestone, D., *Essentials of Pharmacology* (BR) 203
Girdlestone, D., International Union of Pharmacology: member Societies 67
Girdlestone, D., IUPHAR subcommittees / Pat Humphrey / Leslie Benet 29
Girdlestone, D., *Loomis's Essentials of Toxicology* (BR) 203
Girdlestone, D., Pharmaceutical companies in the UK 77
Girdlestone, D., Pharmaceutical Research and Manufacturers of America 79
Girdlestone, D., *see* Bond, R. A. 85
Girdlestone, D., The *TiPS* Advisory Editorial Board 123
Girdlestone, D., The *TiPS* Advisory Editorial Board 124

Girdlestone, D., The top *TiPS* articles 123
Girdlestone, D., *The Year's Drug News 1995* (BR) 203
Godfraind, T., The celebration of 200 issues of *TiPS* 122
Godfraind, T., The International Union of Pharmacology welcomes clinical pharmacologists to Latin America 219
Godson, C., *see* Reppert, S. M. 100
Gonzalez, F. J., *see* McLeod, H. L. (L) 107
Gorenne, I., Norel, X. and Brink, C., Cysteinyl leukotriene receptors in the human lung: what's new? 342
Gozlan, H. and Ben-Ari, Y., NMDA and $GABA_A$ receptors, NO and redox modulation (L) 187
Graham, R. M., Neubig, R. and Lynch, K. R., α_2-Adrenoceptors take centre stage at Nashville meeting 90
Grigoriadis, D. E., *see* Chalmers, D. T. 166
Guidotti, A., *see* Costa, E. 192

H

Halliday, A. J., Careers in the media: life one step away from research 65
Hartig, P. R., Humphrey, P. P., Hoyer, D. and Martin, A. G. R., Alignment of receptor nomenclature with the human genome: classification of $5\text{-}HT_{1B}$ and $5\text{-}HT_{1D}$ receptor subtypes 103
Hartsel, S. C. and Bolard, J., Amphotericin B: new life for an old drug 445
Hayakawa, K., *see* Kohama, K. 284
Hernández, J. and Ribeiro, J. A., Excitatory actions of adenosine on ventricular automaticity 141
Hoflack, J., *Guidebook on Molecular Modelling in Drug Design* (BR) 463
Hökfelt, T., *see* Nicholas, A. P. 245
Hollenberg, M. D., Protease-mediated signalling: new paradigms for cell regulation and drug development 3
Holmén, J., *Successful Scientific Writing* (BR) 202
Holsboer, F., *see* Trapp, T. 145
Hoyer, D., *see* Hartig, P. R. 103
Hughes, I. E., Teaching pharmacology in the UK: a view from academia 32
Humphrey, P. P., *see* Hartig, P. R. 103
Hunyady, L., Balla, T. and Catt, K. J., The ligand binding site of the angiotensin AT_1 receptor 135

I

Iacovelli, L., *see* Chuang, T. T. 416
Ishizaki, T. and Ohnishi, A., Careers in clinical pharmacology: present status and future academic perspectives in Japan 45

J

Jacobson, K. A., Fredholm, B. B., Daly, J. W. and von Lubitz, D. K. J. E., Adenosine receptor ligands: differences with acute versus chronic treatment 108
Johnson, M., *see* Coleman, R. A. 324
Johnson, T. D., Modulation of channel function by polyamines 22
Johnston, G. A. R., $GABA_C$ receptors: relatively simple transmitter-gated ion channels? 319
Jones, R. L., *see* Wise, H. 17
Jones, T., Supporting the industry: the Association of the British Pharmaceutical Industry 50
Kenakin, T., Receptor conformational induction versus selection: all part of the same energy landscape (L) 190
Kohama, K., Ye, L-H., Hayakawa, K. and Okagaki, T., Myosin light chain kinase: an actin-binding protein that regulates an ATP-dependent interaction with myosin 284
Konkoy, C. S. and Davis, T. P., Ectoenzymes as sites of peptide regulation 288
Koroshetz, W. J. and Moskowitz, M. A., Emerging treatments for stroke in humans 227
Kostenis, E. and Mohr, K., Kostenis and Mohr reply (L) 443
Kostenis, E. and Mohr, K., Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation 280
Krieger, C., Lanius, R. A., Pelech, S. L. and Shaw, C. A., Amyotrophic lateral sclerosis: the involvement of intracellular Ca^{2+} and protein kinase C 114
Kuchel, G. A., Resnick, N. M. and Elbadawi, A., The ageing bladder in urinary tract disorders (L) 314
Kuhar, M. J. and Pilotte, N. S., Neurochemical changes in cocaine withdrawal 260

L

Lafontan, M. and Arner, P., Application of *in situ* microdialysis to measure metabolic and vascular responses in adipose tissue 309
Lambert, D. G., *see* Smart, D. 264
Lanier, S. M., *see* Parini, A. 13
Lanius, R. A., *see* Krieger, C. 114
Lazareno, S. and Birdsall, N., Quantitation of allosteric interactions (L) 443
Le, F., Cusack, B. and Richelson, E., The neurotensin receptor: is there more than one subtype? 1
Liberini, P., Valerio, A., Memo, M. and Spano, P., Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? 155
Lipton, S. A., Choi, Y-B., Sucher, N. J., Pan, Z-H. and Stamler, J. S., Redox state, NMDA receptors and NO-related species (L) 186
Lipton, S. A., *see* Sucher, N. J. 348
López-Soriano, F. J., *see* Argilés, J. M. 223
Lovenberg, T. W., *see* Chalmers, D. T. 166
Lundberg, J. M., Modin, A. and Malmström, R. E., Recent developments with neuropeptide Y receptor antagonists 301
Lynch, K. R., *see* Graham, R. M. 90

M

Malcangio, M. and Bowery, N. G., GABA and its receptors in the spinal cord 457
Mallet, J., The *TiPS/TINS* Lecture. Catecholamines: from gene regulation to neuropsychiatric disorders 129
Malmström, R. E., *see* Lundberg, J. M. 301
Mann, J., *Mushrooms: Poisons and Panaceas* (BR) 173
Marley, P. D., *see* Reid, P. M. 205
Marshall, F., *see* Milligan, G. 235
Martin, A. G. R., *see* Hartig, P. R. 103
Martin, W., The agonists and the ecstasy: life as an academic pharmacologist 51
Martin, Y. C., *Chemometric Methods in Molecular Design* (BR) 28
McGrath, J. C., Arribas, S. and Daly, C. J., Fluorescent ligands for the study of receptors 393
McLeod, H. L., Fernandez-Salguero, P. and Gonzalez, F. J., McLeod *et al.* reply (L) 107
Memo, M., *see* Liberini, P. 155
Milligan, G., Marshall, F. and Rees, S., G16 as a universal G protein adapter: implications for agonist screening strategies 235
Modin, A., *see* Lundberg, J. M. 301
Mohr, K., *see* Kostenis, E. (L) 443
Mohr, K., *see* Kostenis, E. 280
Morris, A. J., Engebrecht, J. and Frohman, M. A., Structure and regulation of phospholipase D 182
Morton, I. K. M., *Understanding Medications: What the Label Doesn't Tell You* (BR) 173
Moskowitz, M. A., *see* Koroshetz, W. J. 227
Müller, T., Engels, P. and Fozard, J. R., Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition 294
Munro, S., *Cannabinoid Receptors* (BR) 201
Murgolo, N. J., Brown, J. E., Bayne, M. L. and Strader, C. D., Presenilin mutation in Alzheimer's disease: molecular models suggest a potential functional locus 389

N

Neubig, R., *see* Graham, R. M. 90
Ney, U. M., Pharmacology and biotechnology: a career in clinical development 62
Nials, A. T., *see* Coleman, R. A. 324
Nicholas, A. P., Hökfelt, T. and Pieribone, V. A., The distribution and significance of CNS adrenoceptors examined with *in situ* hybridization 245
Norel, X., *see* Gorenne, I. 342

O

Ohlstein, E. H., *see* Warner, T. D. 177
Ohnishi, A., *see* Ishizaki, T. 45
Okagaki, T., *see* Kohama, K. 284
Ongini, E. and Fredholm, B. B., Pharmacology of adenosine A_{2A} receptors 364

P

Page, C. P., *see* Girdlestone, D. 31
Pan, Z-H., *see* Lipton, S. A. (L) 186
Parini, A., Gargalidis Moudanos, C., Pizzinat, N. and Lanier, S. M., The elusive family of imidazoline binding sites 13
Parker, R. M. C., Bentley, K. R. and Barnes, N. M., Allosteric modulation of $5\text{-}HT_3$ receptors: focus on alcohols and anaesthetic agents 95
Pasternak, G. W. and Standifer, K. M., Pasternak and Standifer reply (L) 217
Paterson, J. W., *see* George, C. F. 317
Pelech, S. L., *see* Krieger, C. 114
Perkins, J. P., Pharmacology education in the USA: II. The role of graduate programmes 42
Perkins, R., *Companion to Pharmacology. A Study Guide For Self-assessment and Revision* (BR) 174
Philippu, A., *see* Singewald, N. 356
Pieribone, V. A., *see* Nicholas, A. P. 245
Pietri-Rouxel, F., *see* Strosberg, A. D. 373
Pilotte, N. S., *see* Kuhar, M. J. 260
Pizzinat, N., *see* Parini, A. 13
Playford, R. J. and Cox, H. M., Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis 436
Power, C. A. and Wells, T. N. C., Cloning and characterization of human chemokine receptors 209

R

Rees, S., *see* Milligan, G. 235

Rees, S. A., Academic research: K^+ channels and an affair of the heart 53
Reid, P. M., Beart, J. J. and Marley, P. D., NO problems down-under 205
Reppert, S. M., Weaver, D. R. and Godson, C., Melatonin receptors step into the light: cloning and classification of subtypes 100
Resnick, N. M., *see* Kuchel, G. A. (L) 314
Ribeiro, J. A., *see* Hernández, J. 141
Richelson, E., *see* Le, F. 1
Roberts, P. J., *see* Toms, N. J. 429
Rosenkilde, M. M., *see* Schwartz, T. W. (L) 347
Rosenkilde, M. M., *see* Schwartz, T. W. 213
Ruffolo, R. R., *see* Wang, X. 276

S

Sallese, M., *see* Chuang, T. T. 416
Salt, T. E., *see* Toms, N. J. 429
Salvemini, D., Preclinical industrial research 58
Schwartz, T. W. and Rosenkilde, M. M., Is there a 'lock' for all agonist 'keys' in 7TM receptors? 213
Schwartz, T. W. and Rosenkilde, M. M., Schwartz and Rosenkilde reply (L) 347
Seale, J. P., Careers in pharmacology: an Australian academic perspective 34
Shaw, C. A., *see* Krieger, C. 114
Simmonds, H. A., *see* Connolly, G. P. (L) 106
Simonato, M. and Beani, L., The neurochemistry of morphine addiction in the neocortex 410
Singewald, N. and Philippu, A., Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis 356
Smart, D. and Lambert, D. G., The stimulatory effects of opioids and their possible role in the development of tolerance 264
Smith, P. F. and Darlington, C. L., Recent advances in the pharmacology of the vestibulo–ocular reflex system 421
Spano, P., *see* Liberini, P. 155
Stamler, J. S., *see* Lipton, S. A. (L) 186
Standifer, K. M., *see* Pasternak, G. W. (L) 217
Stanford, S. C., Stanford replies (L) 401
Stanford, S. C., Prozac: panacea or puzzle? 150
Staton, P. C., *see* Toms, N. J. 429
Strader, C. D., *see* Murgolo, N. J. 389
Strange, P. G., 7TM receptors: 'locks' and 'keys'? (L) 346
Strange, P. G., The energetics of ligand binding at catecholamine receptors 238
Strosberg, A. D. and Pietri-Rouxel, F., Function and regulation of the β_3-adrenoceptor 373
Sucher, N. J., Awobuluyi, M., Choi, Y-B. and Lipton, S. A., NMDA receptors: from genes to channels 348
Sucher, N. J., *see* Lipton, S. A. (L) 186

T

Toms, N. J., Roberts, P. J., Salt, T. E. and Staton, P. C., Latest eruptions in metabotropic glutamate receptors 429
Tonini, M. and Candura, S. M., 5-HT_4 receptor agonists and bladder disorders (L) 314
Trapp, T. and Holsboer, F., Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action 145
Traynor, J. R., *The Pharmacology of Opioid Peptides* (BR) 234
Trist, D. G., *see* Corsi, M. 220
Tuk, B. and van Oostenbruggen, M. F., Solving inconsistencies in the analysis of receptor–ligand interactions 403

V

Valerio, A., *see* Liberini, P. 155
van Oostenbruggen, M. F., *see* Tuk, B. 403
Vardey, C. J., *see* Coleman, R. A. 324
von Lubitz, D. K. J. E., *see* Jacobson, K. A. 108

W

Walker, M. J. A., Pharmacology and education in Canada: a personal perspective 36
Wang, X., Ruffolo, R. R. and Feuerstein, G., mRNA differential display: application in the discovery of novel pharmacological targets 276
Warner, T. D., Elliot, J. D. and Ohlstein, E. H., California dreamin' 'bout endothelin: emerging new therapeutics 177
Weaver, D. R., *see* Reppert, S. M. 100
Webb, D. J., Life as an academic clinical pharmacologist 55
Wells, T. N. C., *see* Power, C. A. 209
Wise, H. and Jones, R. L., Focus on prostacyclin and its novel mimetics 17
Wollemann, M., Orphan receptor or κ_3-opioid receptor? (L) 217
Wright, I. K., *Antimicrobial Chemotherapy* (3rd edn) (BR) 28

Y

Ye, L-H., *see* Kohama, K. 284
Young, A. H. and Ashton, C. H., Pharmacokinetics of fluoxetine (L) 400

Subject Index

compiled by Laurence Errington

A
A127722 178, 179, 180
ABC (ATP-binding cassette) proteins 273–275
Academics in pharmacology
  personal experiences of 51–57
  pharmacology education and careers and the views of
    in Australia 34–36
    in UK 32–34
  research, *see* research
N-Acetyl-aspartylglutamate 431
Acetylcholine
  morphine effects on release 412, 413
  vestibulo–ocular reflex and 423, 426
Acetylcholine receptors
  fluorescent ligand studies 394
  muscarinic, *see* Muscarinic acetylcholine receptors
  vestibulo–ocular reflex and 426
Acetyltransferase transporter, vesicular, gene 132
Acidosis, ubiquitin-dependent proteolysis in skeletal muscle in 225
ACTH-releasing factor, *see* Corticotrophin-releasing factor
Actin-binding proteins 284–287
  myosin light chain kinase as 284–287
  other 285–286
Adenosine
  catecholamines and, interactions 143–144
  ventricular automaticity and excitatory actions of 141–144
Adenosine receptors 108–113, 364–372, 385–386
  A_1 108–113, 385–386
  A_{2A} 108–113, 364–372, 386
    A_{2B} compared with 368
    antagonists 367–371
    distribution 365
    pharmacology 367–371
  A_{2B} 368, 386
  A_{3B} 111, 387
  ligands, acute vs. chronic effects of 108–113
  therapeutic perspectives 111–113, 371, 388
  ventricular automaticity and 142–144
Adenoviral-encoded gene therapy, Parkinson's disease 134
Adipose tissue
  metabolism
    β_3-adrenoceptors and 379
    in situ microdialysis in measurement of 309–313
  vascular response, *in situ* microdialysis in measurement of 309–313
ADP-ribosylation factor family of G proteins and phospholipase D activity 182–183
Adrenaline neurones, central, adrenoceptor subtypes and 249–252
Adrenoceptors 244–255
  central
    localization 245–255
    vestibulo–ocular reflex and 424–425
  nomenclature 246–247
α-Adrenoceptors
  bladder/urethra 162
    antagonists and their effects 164
  fluorescent ligand studies 395, 396, 399
  morphine administration and its effects 413
α_1-Adrenoceptors
  adenosine and 142–143
  CNS, localization 245–246, 251
  subtypes 246
α_2-Adrenoceptors 90–94
  antagonist affinities 91
  CNS
    localization 247, 251
    movement disorders and 254
  drug design and therapeutics with, advances 93
  function 90–91
  physiology, advances 93
  signalling pathways and effector systems 92
  structure 90–91
  subtypes 90–91, 246–247
  targeting and trafficking 93
β-Adrenoceptors
  adenosine and 142
  antagonists in heart failure 419–420
  CNS
    localization 247–248, 251
    movement disorders and 253–254
  fluorescent ligand studies 394, 399
  morphine administration and its effects 413
  pharmacological characteristics of different types 374
  subtypes 247
β_1-Adrenoceptors
  pharmacological characteristics 374
  salmeterol duration of action at 328
β_2-Adrenoceptors
  agonists
    in asthma, phosphodiesterase 4 and tolerance to 331–336
    long-acting, exosites and duration of action of 324–330
  antagonists, reversal of long-acting agonist action by 326–327
  mutant 329, 346 (L)
  pharmacological characteristics 374
  serine residues and ligand binding activity of 346 (L)
β_3-Adrenoceptors 373–381
  agonists 374, 375
  pathology 379
  pharmacological properties 373–375
  physiological role 377–379
  regulation of expression and function 380
  salmeterol duration of action at 328
  structure–function relationships 375–377
  therapeutic aspects 379–380
Adrenocortical steroids, *see* Corticosteroid
Adrenocorticotrophic hormone-releasing factor, *see* Corticotrophin-releasing factor
Aequorin (*A. victoria* green fluorescent protein) 236, 237
Affective disorders, *see* Anxiety; Depression
Ageing bladder and urinary tract disorders 314–315
Agonists (in general)
  affinity, *see* Receptors
  binding sites, classification and importance of molecular biology in determining 87–88
  co-agonism 220–222
  conformational induction as route for receptor activation by 189–191
  efficacy 86
    conformational matching in modelling of 88
    difficulties in estimating 220–222
  G protein-coupled receptors, screening system 235–237
  of seven transmembrane domain receptors, 'lock' for agonist 'keys' 213–216, 346–347 (L)
  stabilizing multiple active states of receptors 190–191
  see also specific receptors
Airway
  cysteinyl leukotriene receptors 342–345
  kinin and tachykinin receptor antagonists and allergic disease of 255–259
  pharmacology, contract research 60–61
β-Alanine, 5-fluorouracil competing with uracil for 107 (L)
Alcohols and 5-HT_3 receptors 95–97
Alimentary tract, *see* Gastrointestinal tract
Allergic disease
  airway, kinin and tachykinin receptor antagonists and 255–259
  phosphodiesterase upregulation in 334–335
Allergic inflammation, *see* Inflammation
Allosteric modulation
  conformational induction as route for receptor activation evidenced by 189–191
  of GABA action 192, 193
    partial 197
  5-HT_3 receptors 95–97
  radioligand dissociation caused by, two-point kinetic experiments quantifying 280–283, 443–444 (L)
Alpha-adrenoceptors, *see* Adrenoceptors
Alprazolam, cognition deficits induced by 198–199
Alzheimer's disease 155–160
  corticotrophin-releasing factor and 170
  heterogeneity 155–160
  Lewy-body dementia and, differentiation 156, 157, 158–159
  presenilin mutations in 389–393
  protein kinase C and 119, 120
Amiloride, structure 14

Amines, biogenic
cardiovascular system and role of 356–361
morphine administration interfering with neurochemistry of 410–412
see also specific (types of) amines
Amino acids
cardiovascular regulation involving 359
excitatory, *see* Excitatory amino acids
inhibitory, receptors, vestibulo–ocular reflex and 424
cis-4-Aminocrotonic acid (CACA) and $GABA_C$ receptors 319, 321
Aminopeptidase A 290–291
Aminopeptidase N 290
3-Aminopropyl(methyl)phosphinic acid (3-APMPA)
as $GABA_C$ antagonist 321
structure 322
3-Aminopropylphosphinic acid (3-APPA)
as $GABA_C$ antagonist 321
structure 322
3-Aminopropylphosphonic acid (3-APA)
as $GABA_C$ antagonist 321
structure 322
cAMP
β_2 agonist (long-acting) effects 327–328
opioid-stimulated formation 265
phosphodiesterase 4 regulation in inflammatory and immunocompetent cells by 332
prostacyclin receptors and 17
cAMP phosphodiesterase type 4 294–298, 331–336
β_2-agonist tolerance in asthma and 331–336
phosphorylation 295, 333–334
subtypes 294–298
chromosomal localization and genomic organization 294
differential splicing 295
distribution and expression 296–297
enzyme activity 295
molecular structure 295, 295–296
rolipram binding, high-affinity 296
selective inhibition 297–298
transcriptional regulation and phosphorylation 295
AMPA receptors and amyotrophic lateral sclerosis 116
Amphotericin B 445–449
mechanism of action 445, 447–448
new delivery systems 445–446
non-fungal pathogens responding to 446–447
toxicity 445, 446, 448
Amyotrophic lateral sclerosis 114–120
Anaesthetics and 5-HT_3 receptors 96, 97–99
Anandamide 201 (BR)
Angiotensin II receptor
type 1 (AT_1), ligand binding site 135–140
type 2 (AT_2), antagonists 136
Angiotensin-converting enzyme as a neuropeptidase 291
Annual Review of Medicine: Selected Topics in the Clinical Sciences 270 (BR)
Annual Review of Pharmacology and Toxicology (Vol. 36) 299 (BR)
Annual Review of Physiology 269 (BR)
Antiarrhythmic drugs, researcher's studies of 53, 54
Antibodies
to extracellular loops of seven transmembrane domain receptors, receptor activation by 214–215
monoclonal, therapeutic applications 450, 453–454
Anticholinesterases, dementia subtypes defined by response to 155–160
Anticoagulants in stroke 229, 231
Anticonvulsant drugs
imidazenil as prototype of new generation of 199
metabotropic Glu receptor agents as 435
Antidepressants, tricyclic, in incontinence 163
Anti-epileptic drugs, imidazenil as prototype of new generation of 199
Antifungal, amphotericin B as 445–446
Antihypertensives, neuropeptide Y_1 receptor agonists as 437
Anti-inflammatory agents in stroke 229, 231
Antimicrobials
amphotericin B as 447
Antimicrobial chemotherapy 28 (BR)
Antinociception and GABA 460
Antiviral activity of amphotericin B 446
Anxiety and corticotrophin-releasing factor 169
Anxiolytic drugs, imidazenil as prototype of new generation of 199
Apoptosis 438–442
chronic inflammation resolved via therapeutic induction of 438–442
defining 438–439
Appetite disorders, corticotrophin-releasing factor and 169
Arachidonyl ethanolamide 201 (BR)
ARL67085 388
Arrestins, characteristics 417
Arrhythmias
adenosine effects 141
researcher's studies of 53, 54
Arthritis, corticotrophin-releasing factor and 170
Association of the British Pharmaceutical Industry 50
Asthma 331–336
contract research pharmacology 60–61
inflammation in, *see* Inflammation
kinins/tachykinins (and their antagonists) in 258–259
phosphodiesterase 4 and β_2-agonist tolerance in 331–336
Atherosclerosis, endothelin and 179
Atopic disease, phosphodiesterase 4 upregulation 334–335
ATP, P_2 purinoceptors and 387–388
ATP-binding cassette proteins 273–275
ATP-dependent actin–myosin interaction, myosin light chain kinase involvement in 273–275
ATP-sensitive K^+ channels, pancreatic, sulphonylurea receptor as regulator of 273–274, 275
Atropine and detrusor function 162
Auditory processes, ATP and 388
Australia, pharmacology careers 34–36

B

Baclofen, spinal cord effects 459–460
Beart, Philip M. 124
Behavioural effects of caffeine (chronic administration) 108–110
Behavioural Pharmacology 66 (SR)
Benzamides and benzimidazolone derivatives, detrusor muscle effects 314
Benzodiazepines 192–199
safer 196–199
research strategies to obtain 196–197
therapeutic use, drawbacks 193–196
Beta-adrenoceptors, *see* Adrenoceptors
Betaseron 452
BIBP3226 301–302, 436
affinity for neuropeptide Y receptors 302
structure 302
vascular effects 303–304
BIBP3435 302
affinity for neuropeptide Y receptors 302
vascular effects 303
Bicuculline-insensitive $GABA_C$ receptors 322
Biomedical multimedia software 66 (SR)
Birdsall, Nigel J.M. 124
Bladder 161–165, 314–316 (L)
ageing 161
disorders 162–165, 314–316 (L)
drug therapy 162–165
types 163
function 161
innervation 161, 162
outflow/outlet
obstruction 163
resistance, altering 164, 314 (L)
sphincter, *see* Urethral sphincter
Blood
flow in adipose tissue, *in situ* microdialysis in measurement of
pressure, brain structures involved in control 358–359
BMS182874 179
BMY45778
actions 20
structure 18
BODIPY in fluorescent ligand studies 394–399
Bonsentan 180–181
Borate dipyrromethene (BODIPY) in fluorescent ligand studies 394–399
Bowery, Norman 124
BQ123 180
Brain
blood pressure regulation and the 358–359
catecholamines and effects of SSRI on uptake by 150–152, 400–402 (L)
corticotrophin-releasing factor and CRF receptors 168–169, 170, 171
infarction, pathophysiology 227–228
ischaemic, *see* Ischaemia
melatonin receptors 100
see also Central nervous system
BRC672 301
Brown adipose tissue, β_3-adrenoceptors and 379
BSc, *see* Pharmacology education

C

CACA and $GABA_C$ receptors 319, 321
Cachexia of cancer and ubiquitin-dependent proteolysis in skeletal muscle 224
Caffeine
adenosine receptors and 108, 369
chronic administration 108
Calcitonin gene-related peptide and vestibulo–ocular reflex 423
Calcium ion(s)
actin-binding proteins and 284–287
intracellular
amyotrophic lateral sclerosis and 118
opioid-induced increases 265, 267
Calcium ion channel blockers in stroke 231
Caldesmon and actin–myosin interactions 285–286
Calmodulin in actin–myosin interactions 284, 285
effects of inhibitors 286
Calponin and actin–myosin interactions 286
Cancer cachexia and ubiquitin-dependent proteolysis in skeletal muscle 224
Cannabinoid Receptors 201 (BR)
Capsaicin ablation of airway sensory neurones 255
2-(Carboxycyclopropyl)glycine analogues 430
4-Carboxyphenylglycine 431
Cardiovascular system
disease, endothelin and 179–180
neurotransmitters (and their receptors) regulating 253, 356–363, 385–386
see also Heart; Vasculature
Careers, *see* Pharmacology careers
Catecholamine(s)

adenosine and 143–144
cardiovascular system and 356–360
as 'keys' for adrenoceptors 213–214
neuropsychiatric disorders and 132–134
receptors
ligand binding, energetics 238–244
vestibulo–ocular reflex and 424–425
SSRI effects on uptake of 150–152, 400–402 (L)
see also Amines; Monoamine *and specific catecholamines/catecholamine receptors*
Catecholaminergic innervation of neocortex, opioid receptors and 411
Cations
GABA-activated Cl^- current-modulating 322
5-HT_3 receptor-modulating 99
Caudal ventrolateral medulla and cardiovascular regulation 362
Caveolin and caveolae 92
CC chemokines 209
receptors 210–211
CCG analogues 430
Cell
death, programmed, *see* Apoptosis
membranes, *see* Membranes
signalling, protease-mediated 3–6
Central nervous system
adenosine A_2 antagonist effects 368, 371
adrenoceptors, *see* Adrenoceptors
cardiovascular homeostasis and 253, 356–363
disorders, *see* Neurological disease
ectoenzyme-mediated neuropeptide metabolism 288–294
nitrergic neurotransmission 207
pyrimidines and 106–107 (L)
see also specific regions
Cerebral cortex
ischaemia, *see* Ischaemia
morphine addiction and 414
Cerebrovascular accident, *see* Stroke
CGP12177 394, 399
CGP35348 460
CGS15943 369, 370
CGS20625 197
CGS21680 365, 366, 369, 370, 371, 386
CGS26303 177–178
Chemokines 209–213
receptors 209–213
cloning/characterization 209–213
in disease 212
types 209
Chemotactic Methods in Molecular Design 28 (BR)
Chloride channels
ABC proteins regulating 273
GABA-gated 319–320, 322
benzodiazepine action on 194–195
8-(3-Chlorostyryl)caffeine in cerebral ischaemia 112
Cholecystokinin and its peptide fragments, bioactivity 291
Choline acetyltransferase (ChAT) gene 131–132
Cholinergic transmission
enhancement/potentiation, strategies 155–157, 159
in Lewy-body dementia 158
drug treatment aimed at 159, 160
morphine effects 412
in voiding disorders 314
Cholinesterase inhibitors and dementia subtypes 155–160
Cicaprost, structure 18
Cirazoline, structure 14
Circadian rhythms and melatonin 100, 102
Clinical drug research 463–464 (BR)
Clinical pharmacology
careers
Germany 48–49
Japan 45–47
UK, personal accounts 55–57, 62, 63
training, Germany 48
Clinical trials, clinical pharmacologists' roles 46
Clonidine, structure 14
Co-agonism in drug–receptor interactions 220–222
Cocaine withdrawal 260–264
Coenzyme Q_{10} in Huntington's disease treatment 339
Cognition
adenosine receptor ligand effects, acute vs. chronic 111
benzodiazepine adverse effects 193–194, 198–199
imidazenil lacking 198–199
Colon, neuropeptide Y receptors 436
Companion to Pharmacology (2nd edn) 174 (BR)
Conference management 65
Contract research pharmacology 60–61
Contraction, smooth muscle, *see* Smooth muscle
Corticosteroid (synthetic), treatment 148–149
Corticosteroid receptors
gene activation by 146–147
heterodimerization increasing functional diversity of corticosteroid action 145–149
clinical implications 148–149
pharmacology 145
Corticotrophin (ACTH)-releasing factor, in CNS disorders
high levels, treatment 171
low levels, treatment 171–172
role 169–170
Corticotrophin (ACTH)-releasing factor receptors 166–172
subtypes 166–167
localization 168–169
nomenclature 168
Corticotrophin (ACTH)-releasing factor-binding protein 167–168
localization 169
pharmacology 167–168
structure 167
Co-transmission in nitrergic nerves 205–207
CP15943 370
CP66713 370
CP96345 256
CP99994 258
CPCCCOEt 431
4CPG 431
RS-CPPG 432
Crawley, Jacqueline 124
Cuello, A. Claudio 125
CXC chemokines 209
receptors 209–210
Cyclic nucleotides
receptor 308
specific, *see* AMP; GMP
Cyclopropan[b]chromen-1a-carboxylate 431
(RS)-α-Cyclopropyl-4-phosphonophenylglycine 432
Cys-loop superfamily of receptors 306
Cysteinyl leukotriene receptors in lung 342–345
Cystic fibrosis transmembrane conductance regulator 273, 308
drug targeting 274–275
structure 274
Cytochrome P450 174 (BR)
SSRI effects on 154
Cytokines in phosphodiesterase 4 regulation 332
Cytomegalovirus, chemokine receptor gene 211

D

'Death' receptors 438–439
Deconvolution methods 395
Degrees in pharmacology, *see* Pharmacology education/training/degree courses
Delivery systems, drug, for
amphotericin B 445–446
δ-opioid receptor 234 (BR)
Dementia subtypes defined by response to anticholinesterases 155–160
see also specific types of diseases/dementia
Dependence liability with benzodiazepines, lack, with imidazenil 198
Depression
bipolar (manic–depressive illness), tyrosine hydroxylase and 132–133
corticotrophin-releasing factor and 169
Dermatitis, atopic, phosphodiesterase 4 upregulation 334
Design, drug, molecular modelling in 463 (BR)
Detrusor muscle
contraction 162
agents reducing contractility 162–164, 164–165, 314–316 (L)
control, 161–162
innervation 161–162
Dihydropyrimidinase deficiency 106
Dihydropyrimidine dehydrogenase deficiency 106 (L), 107 (L)
metabolism 106 (L)
Divaplon 197
Dizocilpine in stroke 229
DMPX 386
DNA transcription factors, glucocorticoid/mineralocorticoid receptor heterodimers interacting with other 147–148
Dollery, Professor Sir Colin, Festschrift in honour of 317–318
L-DOPA, *see* Levodopa
Dopamine
receptors
adenosine A_{2A} receptor interactions 366–367
caffeine and theophylline targeting 110
ligand binding, energetics 238–244
vestibulo–ocular reflex and 424
replacement therapy, Parkinson's disease 133, 339
SSRI effects on uptake of 150, 151, 401 (L)
Dopaminergic system
cocaine withdrawal and 260–263
in Lewy-body disease, drugs aimed at 159, 160
morphine administration and its effects 410–411, 413
Dorsal root ganglion
adrenoceptors in 252–253
opioid stimulatory effects 264–265
DPCPX 367, 369
DPMTX 367, 369
Drug
abuse, cocaine withdrawal 260–264
clinical research 463–464 (BR)
delivery systems for amphotericin B 445–446
design, molecular modelling 463 (BR)
Duffy antigen receptor 209, 211
malaria and 212
Dynorphin, peptide fragment derived from, and its bioactivity 290
Dyskinesias, levodopa-induced, neuronal mechanisms 340–342
Dysrhythmias, *see* Arrhythmias

E

Eating disorders, corticotrophin-releasing factor and 169
Ectoenzyme-mediated neuropeptide metabolism 288–294
EDRF, *see* Nitric oxide

Education, *see* Pharmacology education
Electrolyte homeostasis, neuropeptide Y and peptide YY involvement 436–438
Electrostatic catecholamine receptor–ligand interactions 240–242
Emerging Drugs (Vol. 1) 337 (BR)
β-Endorphin, ectoenzyme-mediated metabolism leading to peptide fragments (and their bioactivity) 290, 292–293
  neuroleptic-induced alterations 292–293
Endothelin 177–181
  mechanisms and regulation of 177
  pathophysiology 179–180
Endothelin receptors 178–179
  antagonists 178–179
    chemistry 178–179
    clinical studies 180–181
    structures 178
Endothelin-converting enzymes 177–178
  inhibitors 177
Endothelium
  leukotriene receptors 344
  NO (endothelium-derived relaxing factor) and NO synthase, *see* Nitric oxide; Nitric oxide synthase
Energy metabolism and β_3-adrenoceptors 379
Enteric nervous system, nitrergic neurotransmission 207
EP157, actions 19
EP185
  actions 19
  structure 19
Epileptic seizures, adenosine receptor ligands and neuroprotection from, acute vs. chronic administration 111–112
Erythropoietin 451
Essentials of Pharmacology 203 (BR)
Ethanol and 5-HT_3 receptors 95, 96
5′-*N*-Ethylcarboxamide adenosine (NECA) 142, 143
Excitatory amino acids
  amyotrophic lateral sclerosis and 114–116
  Huntington's disease and 339
  receptors 306
    vestibulo–ocular reflex and 423–424
Exosites and duration of action of long-acting β-agonists 324–330
Extracellular fluid in adipose tissue, *in situ* microdialysis in measurement of substances in 312

F

Fas-mediated death and chronic inflammation 438–442
Fat cells, secretory activity 312–313
8FB-PTP 370
F_2CCG-I 430
Finasteride in benign obstructive prostatic hyperplasia 164
FK224 258
FK888 258
Flow cytometry 395
FLP55712 343
Fluorescent ligands, receptor studies 393–399
Fluorinated pyrimidines, neurotoxicity 106 (L), 107 (L)
Fluoxetine 150–154, 400–402 (L)
Food deprivation, ubiquitin-dependent proteolysis in skeletal muscle 224
Formeterol 324
  characteristics of duration of action 325–330
Fozard, John R. 125
FR139317 180
Fredholm, Bertil B. 125
Free radical scavengers in stroke therapy 229, 230
Freelance medical writing from home 64–65

G

G protein(s)
  G protein-coupled receptor interactions with 91–92
  phospholipase D activity and 182
  universal adapter, G_{16} as a 235–237
G protein-coupled receptor(s) 416–421
  agonists, screening system 235–237
  β_3-adrenoceptors as 375–376
  desensitization 416–421
    heterologous 418–420
    homologous 416–417
  GTP effects 189
  interactions with G proteins 91–92
    promiscuity 89
  melatonin receptors as 100–102
  two-state model 88
G protein-coupled receptor kinases 417–420
  characteristics 416
  gene expression and activity, regulation 418–419
  receptors phosphorylated by 417
GABA 457–462
  cardiovascular regulation involving 359
  chloride channels gated by, *see* Chloride channels
  morphine administration and its effects 412, 413, 414
  in spinal cord 457–462
    localization 458
    physiology 458–459
  vestibulo–ocular reflex and 423, 424
GABA receptors (in general)
  in spinal cord 457–462
    location 457
  vestibulo–ocular reflex and 424
$GABA_A$ receptors 192, 319, 457
  agonists/partial agonists 320–321
  antagonists 321–322
  benzodiazepine ligands for 192–193
    for specific receptor subtypes 196–199
  $GABA_B$ receptor properties compared with 320
  $GABA_C$ receptor as subclass of 323
  $GABA_C$ receptor properties compared with 320
  redox modulation 186, 188
  in spinal cord 457–462
    location 457
$GABA_B$ receptors 319, 457
  properties compared with $GABA_A$/$GABA_C$ receptors 320
  in spinal cord 457–462
    antinociception and 460
    baclofen effects 459–460
    location 457
$GABA_C$ receptors 192, 319–323
  $GABA_A$ receptor properties compared with 320
  as $GABA_A$ receptor subclass 323
  $GABA_B$ receptor properties compared with 320
  spinal cord 457
Gastrointestinal Drug Therapy, Handbook of 174 (BR)
Gastrointestinal tract
  nervous system, nitrergic neurotransmission 207
  neuropeptide Y and peptide YY effects 436
Gehrig's disease 114–120
Gene(s)
  cerebral ischaemia-activated 232
  chemokine receptor 212
  corticosteroid receptor-activated 146–147
  novel, mRNA differential display 276–279
    compared with, subtractive library screening for discovering 277
  reporter, in G protein-coupled receptor agonist screening 236–237
  see also specific genes
Gene therapy 450–451, 454–455
  Parkinson's disease 133–134
General anaesthetics and 5-HT_3 receptors 96, 97–99
Genetic polymorphisms, hepatic drug metabolism and 46
Genome, human, 5-HT_{1B} and 5-HT_{1D} subtype classification and the 103–105
Germany, pharmacology careers 47–49
Globus pallidus (GP) and Parkinson's disease 339–340
Glucocorticoid receptors
  effects mediated *in vivo* 145–146
  heterodimerization with mineralocorticoid receptors increasing functional diversity of corticosteroid action, *see* Corticosteroid receptors
  pharmacology 145
Glutamate
  cardiovascular regulation and 361–362
  glycine and, co-agonism at NMDA receptors 220–222
  metabotropic Glu receptors regulating release of 432–433
  morphine administration and its effects 412, 413
  transporters 308
  vestibulo–ocular reflex and 422
Glutamate receptors 429–435
  metabotropic 429–435
    drugs for 430–432
    ionotropic and, interactions 433–434
    molecular characterization 429–430
    neurodegenerative diseases and 116, 435
    signal transduction and 433–434
    synaptic transmission and role of 434–435
    transmitter release and 432–433
  stroke therapy aimed at blocking 228–230
  see also specific types
Glycine (and NMDA receptors)
  glutamine co-agonism with 220–222
  subunit-dependent difference in binding 351
GMP, cyclic, NO and 207
Godfraind, Théophile 125
Good Laboratory Practice 175 (BR)
GR31354 328
GR35795 328
Graduate education in Canada 36–38
GTP effects on G protein-coupled receptors 189
GTPase and α_2-adrenoceptors 91
Guanabenz, structure 14
Guide to Clinical Drug Research 463–464 (BR)
Guidebook on Molecular Modelling in Drug Design 463 (BR)
Gut, *see* Gastrointestinal tract

H

Hadden, John 7
Halogenated alcohols and 5-HT_3 receptors 95–97
Haloperidol, neuropeptides/neuropeptidases and effects of 292, 293
Halothane and 5-HT_3 receptors 96, 97
Handbook of Gastrointestinal Drug Therapy 174 (BR)
Heart
  failure
    congestive, endothelins in 179–180, 180–181
    G protein-coupled receptor kinases and arrestins and 419–420
  ischaemia, adenosine receptor antagonists in 371, 385–386

K^+ channels, academic researcher's studies of 53–55
ventricular automaticity, excitatory actions of adenosine 141–144
Hepatic drug metabolism, *see* Metabolism
Heroin addiction, cerebral cortex and 414
Herpes saimiri virus, chemokine receptor gene 211
Hill factor 403, 406
Histamine
cardiovascular regulation 359
fluorescein-labelled, studies employing 395
receptors, vestibulo–ocular reflex and 425–426
HIV and amphotericin B 446
Hoe140 257
Home, freelance medical writing 64–65
Hormone-like signals to cells, protease involved in conveying 3–6
Hormone therapy, lower urinary tract conditions 164
Hughes, John 7
Huntington's disease
prevention of neurodegeneration 339
protein kinase C and 119
Hydrogen bonding interactions, catecholamine receptor–ligands 242–243
Hydrophilicity of fluorescently labelled ligands 399
Hydrophobic interactions, catecholamine receptor–ligands 243
5-Hydroxyindole and 5-HT_3 receptors 99
5-Hydroxytryptamine (serotonin)
cardiovascular regulation and 360–361
neurones containing, SSRI effects on activity of 152
receptors
5-HT_{1B}, classification 103–105
5-HT_{1D}, classification 103–105
5-HT_3, allosteric modulation 95–97
5-HT_4, agonists, bladder disorders and 314–316 (L)
vestibulo–ocular reflex and 425
5-Hydroxytryptamine reuptake inhibitors, selective (SSRI) 150–154, 400–402 (L)
Hypertension 317
endothelins in 180
clinical studies employing receptor antagonists of 180–181
neuropeptide Y_1 receptor agonists in 437
pulmonary, *see* Pulmonary hypertension
Hypothalamo–pituitary–adrenal activity in multiple sclerosis, steroid treatment and 149
Hypothalamus and cardiovascular system 356–358
Hypothermia in stroke, neuroprotective effects 230–231

I

IB-MECA effects on induced seizures 111, 112
Icatibant 257
Imidazenil 197
pharmacological profile 197–199
Imidazoline binding sites 13–16
characteristics 15
classification 13
clinical perspectives 15–16
functional activity 14–15
structural properties 13–14
Imipramine in incontinence 163
Immune system
cannabinoid receptors 201 (BR)
kinin and tachykinin interactions 256–258
Immunocompetent cells, phosphodiesterase 4 regulation in 332
In situ hybridization in examination of CNS adrenoceptors 245–255
In situ microdialysis in measurement of metabolic and vascular response in adipose tissue 309–313
Incontinence, urinary
stress, *see* Stress incontinence
treatment 161–163, 314–316 (L)
Industry, pharmaceutical research, *see* Research
trade association representing 50
Infection, ubiquitin-dependent proteolysis in skeletal muscle 224–225
Inflammation/inflammatory disorders
airway, kinin and tachykinins and 256, 257
allergic (especially asthmatic) 317
β_2-agonist inability to relieve, mechanism 331
chemokines and 212
chronic
GABA and the spinal cord and 461
therapeutic induction of apoptosis in the resolution of 438–442
corticotrophin-releasing factor and 170
Inflammatory cells, phosphodiesterase 4 regulation in 332, 334
Information about drugs, layman's guide 173 (BR)
Inhibitory amino acid receptors and vestibulo–ocular reflex 424
Injury, ubiquitin-dependent proteolysis in skeletal muscle 224–225
Inositol (1,4,5)-trisphosphate, opioid-stimulated formation 265–266
Insulin receptor, proteases and 4
Interactions, drug–drug, Japanese research 46
Interactive Multimedia Examination System 66 (SR)
Interferon-β, recombinant 452
Interferon-γ and cAMP phosphodiesterase 334
Interleukin-8 receptor 209–210
International Union of Pharmacology meeting in Latin America (1996) 219
on receptor classification 85–89, 103–105
Interomedial lateral cell column and cardiovascular regulation 362
Intestinal nervous system, nitrergic neurotransmission 207
N^6(3-Iodobenzyl)-5′-*N*-methylcarboxyamidoadenosine (IB-MECA) effects on induced seizures 111, 112
Ion channels
ABC proteins regulating 273–275
blockers
NMDA receptor subunit-dependent differences of 351
in stroke therapy 229, 231
ligand-gated, classification 87, 88–89
receptors coupled to/influencing 433–434
quantitative information provided by 88–89
redox modulation 186
transmitter-gated, *see* Neurotransmitters
voltage-gated 229, 231
see also specific channels
Irritable bladder conditions 163
Ischaemia
cardiac, adenosine receptor antagonists in 371, 385–386
cerebral
adenosine receptor ligand administration in neuroprotection from, acute vs. chronic administration 112
injury due to, cellular mechanisms 230
see also Stroke
Isocortex and morphine addiction 410–415

J

Japan, clinical pharmacology careers 45–47
Joint inflammation, corticotrophin-releasing factor and 170

K

Kainate receptors and amyotrophic lateral sclerosis 116
κ-opioid receptor 234 (BR)
κ_3-opioid receptor, *KOR3* clone as 217–218 (L)
Ketamine and 5-HT_3 receptors 96, 97
KF17837 367, 369, 370
Kidney
neuropeptide Y and peptide YY effects 436–437
pathology, endothelins and 180
Kinetic theory, receptor 324–325
Kinin receptor antagonists and allergic airway disease 255–259
KOR3 clone 217–218 (L)

L

L754142 178, 179
L-type Ca^{2+} channel blockers in stroke 231
Lazdunski, Michel 125
Lead discovery, pharmacological, peptide libraries in 8–12
Leff, Paul 125–126
Leishmaniasis, amphotericin B 446
Leptin receptor 379
Leukotriene receptors in lung 342–345
Levodopa/L-DOPA
administration
dyskinesias with, neuronal mechanisms 340–342
in Parkinson's disease 339, 340–342
endogenous, cardiovascular effects 362
Lewy-body dementia 155–160
Alzheimer's disease, differentiation 156, 157, 158–159
drug therapy, clinical responsiveness 159, 159–160
Lewy-body pathology 158, 159
Ligand(s)
fluorescent 393–399
affinity 398
selectivity 398
studies employing 393–399
inconsistencies in receptor interactions, solving 403–409
ion channels gated by, classification 87, 88–89
as 'key' to receptor active states 213–216
protean 88
mutational analysis of interactions with receptor ligands 241, 242, 346 (L)
see also Radioligands *and specific receptors and ligands*
Limbird, Lee 126
Lipid formulations of amphotericin B 445, 446
Lipid metabolism, β_3-adrenoceptors and 379
Lipid solubility of long-acting β_2 agonists 328
Lipolysis, *in situ* microdialysis in measurement of 312
Lipoprotein, low-density, amphotericin B binding to 446, 448
Liposomal preparations of amphotericin B 445, 446
Liver, drug metabolism, *see* Metabolism
LMB7 453–454
Locus coeruleus
adrenoceptors in 252
cardiovascular system and 356–359
morphine administration and 412, 414
Lommis's Essentials of Toxicology 203 (BR)

Long-term potentiation and depression, metabotropic Glu receptors and 435
Lou Gehrig's disease 114–120
Low-density lipoprotein, amphotericin B binding to 446, 448
Lung, cysteinyl leukotriene receptors 342–345
see also Airway
LY354740 430
LY341495 432

M
Macrokinetic theory, receptor 325
Macrophage inflammatory protein 1α 211
Malaria and duffy antigen receptor 212
Malignancy-associated cachexia and ubiquitin-dependent proteolysis in skeletal muscle 224
Malnutrition and ubiquitin-dependent proteolysis in skeletal muscle 224
Manic–depressive illness, tyrosine hydroxylase and 132–133
MCPG 431
Media-based careers 64–65
Medical writing, *see* Writing
Medication, layman's guide 173 (BR)
Medullary structures involved in cardiovascular regulation 359–361, 361–362
Melatonin 100
  receptors 100–102
    cloning 100–102
    identification 100
  therapeutic potential 102
Meldolesi, Jacopo 126
Membranes
  artificial, salmeterol and 329
  cell
    β_2-adrenoceptor agonist binding profiles 326
    NMDA receptor subunit topology 349
    see also Transmembrane domain receptors
Memory, acute vs. chronic affects of adenosine receptor ligands 111
Mephenytoin-type oxidation, genetic differences 46
Mesolimbic neurones and cocaine withdrawal 260–264
Metabolic acidosis, ubiquitin-dependent proteolysis in skeletal muscle in 225
Metabolism
  adipose tissue, *see* Adipose tissue
  drug (in liver)
    genetic differences 46
    toxicity and 317–318
Metabotropic glutamate receptors, *see* Glutamate receptors
[Met]enkephalin, neuroleptic effects on degradation 293
N-Methyl-D-aspartate receptors, *see* NMDA receptors
α-Methyl-4-carboxyphenylglycine 431
[^{3}H]*N*-Methylscopolamine binding to muscarinic ACh receptors, allosteric modulators affecting 443–444 (L)
Meynert's nucleus basalis, *see* Nucleus basalis of Meynert
Microdialysis, *in situ*, in measurement of metabolic and vascular response in adipose tissue 309–313
Microkinetic theory, receptor 325, 328
Microscopy, confocal 395, 398
Mineralocorticoid receptors
  effects mediated *in vivo* 145–146
  heterodimerization with glucocorticoid receptors increasing functional diversity of corticosteroid action 145–149
  pharmacology 145
Molecular modelling in drug design 463 (BR)
Monoamine
  extracellular fluid levels, SSRI effects on 152–153
  as 'keys' for adrenoceptors 213–214
  uptake, SSRI effects on 150–152, 401 (L)
  see also Amines; Catecholamines *and specific monoamines/monoamine receptors*
Monoamine oxidase-A/B as imidazoline binding sites 13–16
Monoclonal antibodies, therapeutic applications 450, 453–454
Monocyte(s), atopic 334–335
Monocyte chemotactic proteins 211
Monte Carlo simulation of peptide library synthesis 9
Mood disorders, *see* Anxiety; Depression
Morphine addiction, neocortex and 410–415
Motor neurone disease (amyotrophic lateral sclerosis) 114–120
Movement disorders 339–342
  adrenoceptors and 253–254
  new treatments 339–342
MS8209 446
MSc courses in pharmacology, Canada 37
Multimedia software, biomedical 66
Multiple sclerosis, steroid treatment and hypothalamo–pituitary–adrenal activity in 149
μ-opioid receptor 234 (BR)
Muscarinic acetylcholine receptors
  detrusor muscle 161
    effects of antagonists 162–163
  radioligand binding to, allosteric modulators affecting 443–444 (L)
Muscle, *see* Skeletal muscle; Smooth muscle
Mushrooms, Poisons and Panacea 173 (BR)
Mutational analysis of receptor–ligand interactions 241, 242, 346 (L)
c-myc and carcinogenesis 317
Myocardial cell, adrenoceptor–adenosine receptor interactions 143
Myosin light chain kinase 284–287

N
N-type Ca^{2+} channel blockers in stroke 231
NAAG 431
NBQX in stroke 229–230
Neocortex and morphine addiction 410–415
Neprilysin 289–290
Nerve growth factor effects in dementia 156–157
Neurodegeneration (and neurodegenerative disorders)
  metabotropic Glu receptors and 116, 435
  prevention 339
  protein kinase C in, *see* Protein kinase C
Neuroleptics and neuropeptides/neuropeptidases 292–293
Neurological disease/disorders (CNS disorders)
  bladder dysfunction due to 163
  corticotrophin-releasing factor in, *see* corticotrophin-releasing factor
  imidazoline binding sites and 15–16
  see also specific (types of) disorders
Neurolysin 291
Neurones
  levodopa-induced dyskinesias and the role of 340–342
  NO synthase, *see* Nitric oxide synthase
  PGI_2 action 18
Neuropeptide(s) 288–294
  drug effects on 291–292
    morphine 412, 413
  metabolism, peptidases and 288–294
  vestibulo–ocular reflex and 423, 426
Neuropeptide Y 301–304, 436–438
  receptors 301–304, 436, 437
    agonists 437
    antagonists 301–304, 436
    subtypes 301, 437
  in spinal cord 458
  in sympathetic vascular control 302–304
Neuroprotection
  from cerebral ischaemia, adenosine receptor ligand administration in, acute vs. chronic administration 112
  from NMDA toxicity, metabotropic Glu receptor agonists in 435
  from seizures, adenosine receptor ligand administration in, acute vs. chronic administration 111–112
Neuropsychiatric disorders, tyrosine hydroxylase and 132–134
Neurotensin
  fluorescently labelled, studies employing 395
  gene expression, haloperidol effects 292
  peptide fragments derived from, bioactivity 290, 291
  receptor 1–3
Neurotoxicity, fluorinated pyrimidines 106 (L), 107 (L)
Neurotransmission
  metabotropic Glu receptors and their role in 434–435
  nitrergic nerves, *see* Nitrergic nerves
  NPY-mediated, in sympathetic vascular control 302–304
Neurotransmitters
  cardiovascular regulation and 253, 356–363, 385–386
  inhibitory, detrusor muscle and 161
  metabotropic Glu receptor regulating release of 432–433
  morphine effects 410–415
  receptors and ion channels gated by 305–309
    classification 87, 305–306
    superfamilies 307
  see also Co-transmission *and specific transmitters*
Neurotrophins in stroke therapy 229, 230
Neutral endopeptidase inhibitors, tachykinin activity terminated by 255–256
Nicotinic receptors, fluorescent ligand studies 394
Nitrergic nerves 205–208
  biochemical markers 205
  neurotransmission 205–208
    co-transmission 205–207
    pathophysiology 207–208
Nitric oxide (EDRF) 186–189, 205–208
  detrusor muscle and effects of 162
  NMDA receptors and 186–189, 207
  Parkinson's disease and 339
  researchers personally studying 51, 59
Nitric oxide synthase
  neuronal
    stroke and 232
    tetrahydrobiopterin as cofactor in 205
  vascular endothelial, stroke and 232
NMDA receptors 186–189, 220–222, 348–355
  agonists, co-agonism between glutamate and glycine 220–222
  amyotrophic lateral sclerosis and 116–117
  antagonists
    interactions 222
    in stroke therapy 228–229
  metabotropic Glu receptor agonists suppressing activity of 435
  NO and 186–189, 207
  number expressed in individual cell 354–355
  number of functionally different (*in vivo*) 354
  polyamines and 22–24
  recombinant vs. native, molecular basis for difference between 352–353
  redox modulation 186–189, 352
  subunits 23–24, 348–352, 353–354

affecting neighbouring subunits 349–350
membrane topology 349
newly identified 353
pharmacology of specific 350–351
stoichiometry 348–349
see also NR1; NR2
vestibulo–ocular reflex and 422, 424
NO, *see* Nitric oxide
Nociceptin 217 (L)
Nociception and GABA 460–462
Noradrenaline
SSRI effects on uptake of 150, 151
vestibulo–ocular reflex and 424–425
Noradrenaline neurones, central, adrenoceptor subtypes and 249–252
Noradrenergic system and effects of morphine administration 411–412
NR1 subunit of NMDA receptor 23, 24, 348–352
expression in absence of functional channels 354
forming functional channels in *Xenopus* oocytes but not mammalian cells 348–349
isoforms, single or multiple in individual receptors 349
NR2 subunit of NMDA receptor 23–24, 348–352
NR-L subunit of NMDA receptor 353
Nucleus basalis of Meynert
Alzheimer's disease and 155
Lewy-body disease and 159
Nucleus tractus solitarius, cardiovascular system and 357, 359–360, 361–362
Nutritional deficit, ubiquitin-dependent proteolysis in skeletal muscle 224

O

Obesity and β_3-adrenoceptors 379
therapeutic aspects 379–380
Octibamate
actions 19–20
structure 18
Oculovestibular reflex system 421–427
Oestrogen therapy in stress incontinence 164
Opioid(s), endogenous 410
stimulatory effects and the development of tolerance 264–269
Opioid receptors 410
fluorescent ligand studies 394–395
κ-, *see* κ-opioid receptor
pharmacology 234 (BR)
vestibulo–ocular reflex and 426
Orphan receptors
chemokine receptor-like 211–212
KOR3 clone classified as 217–218 (L)
Orphanin-FQ 217 (L)
Otsuka, Masanori 126
Oxybutynin, detrusor contractility reduced by 163
Oxygen radical scavengers in stroke therapy 229, 230

P

P-glycoprotein 273
structure 274
P-region of transmitter-gated channels 208, 306
p55 tumour necrosis factor receptor-1 438–439
Page, Clive 7, 126
Pain, chronic, GABA and the spinal cord and 460–461
Pancreatic ATP-sensitive K^+ channels, sulphonylurea receptor as regulator of 273–274, 275
Parasitic Diseases, WHO Prescribing Information 175 (BR)
Parkinson's disease 339–341
prevention of neurodegeneration in 339
protein kinase C and 119
therapy 339–340
dopamine replacement 133, 339
gene 133–134
surgical 339–340
in vivo evidence for current model 340
PD154804 178, 179
PD156707 179, 180
PEG-superoxide dismutase 230
Peptidases
inhibitors of, tachykinin activity terminated by 255–256
neuropeptide metabolism and the role of 288–294
Peptide(s), nervous system, *see* Neuropeptides
Peptide libraries, combinatorial synthesis of 8–12
statistical considerations 8–12
Peptide ligands for angiotensin receptor type 1 (AT_1) 136, 137–139
Peptide YY 436–438
Pharma – CAL – ogy 66 (SR)
Pharmaceutical Dosage Forms: Disperse Systems (Vols 1/2) 382–383 (BR)
Pharmacology (M. Ebadi, 3rd edition) 203 (BR)
Pharmacology (Rang and Dale, 3rd edition), *companion to* (2nd edition) 174 (BR)
Pharmacology, Essentials of 203 (BR)
Pharmacology and Toxicology, Annual Review (Vol. 36) 299 (BR)
Pharmacology careers 31
Australia 34–36
Canada 38
Germany 47–49
Japan 45–47
personal accounts 53–65
UK 33, 53–57
Pharmacology education/training/degree courses (and teaching) 31
graduate/higher
Canada 36–38
Japan 46
USA 42–45
see also PhDs
undergraduate (BSc etc.)
Australia 34–36
Canada 38–39
UK 32–34
USA 40–42
Pharmacology of Opioid Receptors 234 (BR)
Pharmacology research, *see* Research
PhDs in pharmacology
Canada 37
UK, personal account of experience 58–59
USA 42–45
Phosphatidic acid and cAMP phosphodiesterase 334
Phosphatidylcholine hydrolysis, phospholipase D-catalysed 182
Phosphatidylinositol 4,5-bisphosphate and phospholipase D activation 182–183
Phosphodiesterase 4, *see* cAMP phosphodiesterase type 4
Phosphoinositide hydrolysis, opioid-stimulated 265–266
Phospholipase C, opioid effects 265, 266
Phospholipase D 182–185
classification 185
interspecies structural comparisons 183–185
metabotropic Glu receptors and 433
regulation and function 182
Phosphoramidon 256
Phosphorylation (of proteins)
cAMP phosphodiesterase type 4 295, 333–334
G protein-coupled receptors 417
in neurodegenerative disorders
amyotrophic lateral sclerosis 117–119
in other disorders 119–120
Picrotoxin and $GABA_C$ receptors 322
Pima Indians, hereditary obesity 379
Piperadine-4-sulphonic acid (P4S) as $GABA_C$ receptor antagonist 321, 322
Pituitary adenylate cyclase activating polypeptide ligands 86
Plant phospholipase D, structure 183–185
Plasma extravasation, airway 257
Plasminogen activator
recombinant 453, 456
tissue 453, 454, 456
in stroke 231
Plasmodium vivax and duffy antigen receptor 212
Poisoning, *see* Toxicity
Poisson distribution, peptide library design and 8, 9, 10, 11
Polyamines, modulation of channel function by 22–27
Polymerase chain reaction-based methods of uncovering differentially expressed genes 276
Pore region of transmitter-gated channels 208, 306
Postgraduate education in Canada 36–38
Postsynaptic neurones and cocaine withdrawal 261–262
Potassium ion channels
cardiac, academic researcher's studies of 53–55
non-receptor, transmitter-gated channels with similarities to 307–308
openers, detrusor contractility and effects of 163
pancreatic ATP-sensitive, sulphonylurea receptor as regulator of 273–274,
polyamines and 25–26
prostacyclin receptors and 17–18
Practical Pharmacology 66 (SR)
Prazosin, fluorescently labelled 395–398
Preclinical industrial research, personal account of career 58–60
Presenilin mutations in Alzheimer's disease 389–393
Presynaptic neurones and cocaine withdrawal 261–262
Prion disease, amphotericin B 446–447
Pro Fit 464 (SR)
Progress in Drug Research (Vol. 45) 174–175 (BR)
Prostacyclin (PGI_2) 17–21
Prostacyclin receptors (IP)
agonists/mimetics, novel 18, 19–21
therapeutic uses 20–21
molecular biology 17
Prostanoids, bladder effects 162
Prostatic hyperplasia, benign obstructive, hormone therapy 164
Protease-mediated signalling 3–6
Protein(s)
deficiency, ubiquitin-dependent proteolysis in skeletal muscle 224
phosphorylation, *see* Phosphorylation *and specific kinases*
recombinant, therapeutic 450–456
Protein kinase C
G protein-coupled receptor kinase interaction with 418
glutamate release and 433
in neurodegenerative disorders
amyotrophic lateral sclerosis 117–119
in other disorders 119–120
opioid effects 266–267
Proteolysis in skeletal muscle, ubiquitin-dependent 223–226
Proton inhibition at NMDA receptors, tonic, polyamines stopping/reversing 24
Protozoal infections, amphotericin B 446
Prozac 150–154, 400–402 (L)
Publishing, *see* Writing
Pulmonary hypertension
endothelin and 180

prostacyclin receptor agonists in 20–21
Purines 385–388
glutamate system and, inter-relationship and 432–433
Purinoceptors 385–388
P_2 387–388
P_{2X} 307–308
therapeutic perspectives 388
Purkinje cells and metabotropic Glu receptors 434
Pyrimidines 106–107 (L)
CNS activity and levels of 106 (L)
fluorinated, neurotoxicity 106(L), 107 (L)
metabolism, physiological role 107 (L)

Q

Quantitative Structure–Activity Relationships 28 (BR)
Quast, Ulrich 126–127
Quinazoline, fluorescently labelled 395–398

R

Radioligands 404
in CNS adrenoceptor distribution studies 245, 247, 248–249
dissociation, allosteric effects on, two-point kinetic experiments quantifying 280–283, 443–444 (L)
fluorescent ligands compared with 394
Receptors 85–89
activation, conformational induction as route for 189–191
active states
ligands as 'key' to 88, 213–216
multiple, agonists stabilizing 190–191
affinity estimates (for agonists/antagonists) 85–86
difficulties and errors in estimating 220–222, 403–409
agonists, *see* Agonists
allosteric modulation, *see* Allosteric modulation
characterization, modern approach to 85
classification 85–89, 103–105, 305–306
of ligand-gated receptors 87, 88–89
modern approach to 85
species variation and 86–87
structural information providing basis for 86
transductional information and 89
of transmitter-gated receptors, *see* Neurotransmitters
co-agonism 220–222
'death' 438–439
G protein-coupled, *see* G protein-coupled receptors
ion-gated, quantitative information provided by 88–89
kinetic theory 324–325
ligands, *see* Ligands
occupation model 403–409
derivation 403–404
reformulation 404–409
theoretical inconsistency 404–406
recombinant, *see* Recombinant receptors
selectivity, of fluorescent ligands 398
single- vs. two-state model 88
SSRI binding to various 153–154
see also specific receptors
Recombinant proteins, therapeutic 450–456
Recombinant receptors
assays 85–86
NMDA, molecular basis for difference between native receptor and 352–353
Redox modulation
$GABA_A$ receptors 186, 188
NMDA receptors 186–189, 352
5α-Reductase inhibitors in benign obstructive prostatic hyperplasia 164
Reidenberg, Marcus M. 127
Remington: The Science of Practice and Pharmacy 175 (BR)
Renal studies, *see* Kidney
Reporter genes in G protein-coupled receptor agonist screening 236–237
Research
academic
UK 33, 53–54, 56–57
USA 41–42, 42–45
clinical drug 463–464 (BR)
industrial
Australia 35
Canada 38
contract research 60–61
preclinical, personal account of career 58–60
writing-up 202
Resin beads in combinatorial synthesis of peptide libraries 8, 9, 10, 11, 12
Respiratory tract, *see* Airway
Reteplase 453, 456
Retina, $GABA_C$ receptors 319–320
Reverse transcription in mRNA differential display 276
Rhinitis, allergic, kinins/tachykinins (and their antagonists) in 258–259
Rho-related G proteins and phospholipase D activity 182–183
ρ-subunits of $GABA_C$ receptors 319–320, 322–323
mRNA
adrenoceptors in CNS, localization 245–255
differential display 276–279
advantages 278
confirmation of differentially expressed genes 277–278
identification of differentially expressed genes 278
limitations 278
methodology 276–277
phosphodiesterase 4 isogenes, patterns of expression 294
Ro198022 197
Rolipram binding by cAMP phosphodiesterase type 4 subtypes, high-affinity 296
Rostral ventrolateral medulla and cardiovascular regulation 358, 359, 360
Ruffulo, Robert R. (Jr) 127

S

S182 (presenilin 1) 389–393
Saccharomyces cerevisiae (yeast) phospholipase D, structure 183–185
Salmeterol 324
characteristics of duration of action 325–330
SB209598 178, 179
SB209670 178, 180
SB217242 180
SCH58261 368, 369, 371, 386
Second messengers
methodology for analysis 236–237
opioid effects on 264–267
see also Signal transduction
Seizures, adenosine receptor ligands and neuroprotection from, acute vs. chronic administration of 111–112
Selegiline in Huntington's disease 339
Sensory neurones
airway, capsaicin ablation 255
bladder 162
drugs affecting 164
primary, adrenoceptor modulation 252–253
Serine residues of β_2-adrenoceptors and ligand binding activity 346 (L)
Serotonin, *see* 5-Hydroxytryptamine
Seven transmembrane domain receptors (7TM) 306, 346–347 (L)
'lock' for agonist 'keys' 213–216, 346–347 (L)
Signal transduction
α_2-adrenoceptors and 92
chemokine receptors and 212
G protein-coupled receptors and 89
caveolin and 92
cross-talk 420
glutamate receptors and 433–434
opioid-induced stimulatory 267
protease-mediated 3–6
receptors (in general) producing, classification 305, 306
transductional information and its importance in 89
see also Second messengers
Signal Transduction Protocols 201 (BR)
Skeletal muscle
baclofen as relaxant 459–460
ubiquitin-dependent proteolysis in 223–226
Sleep disorders, circadian-based, treatment 102
Smooth muscle contraction
actin-binding proteins and 284–287
detrusor, *see* Detrusor muscle
leukotrience receptors and 343–344
Sodium ion channels, non-receptor, transmitter-gated channels with similarities to 307–308
SoftShell Properties 464 (SR)
Solitary tract, nucleus of, cardiovascular system and 357, 359–360, 361–362
Spermine
NMDA receptors and 23
structure 23
Spinal cord
cardiovascular regulation and 359–360
GABA and its receptors in, *see* GABA; GABA receptors
SPO14 and its product 183, 184, 185
SR48692 1–2, 3
SR48968 256
SR95531 322
SR120107A 302
SR120819A 301, 302
structure 302
SR120107A
structure 302
vascular effects 303
Starvation and ubiquitin-dependent proteolysis in skeletal muscle 224
Steroid, *see* Corticosteroid; Corticosteroid receptors
STM2 (presenilin 2) 389–393
Strader, Catherine 7, 127
Stress incontinence 163
oestrogen therapy 164
Striatal adrenoceptors 253–254
Stroke, ischaemic 227–233
corticotrophin-releasing factor and 170
pathophysiology of brain infarction 227–228
pharmacological strategies 228–233
new 232–233
therapeutic window 227–228
Substance P
peptide fragments derived from, and their bioactivity 290, 293
vestibulo–ocular reflex and 423, 426
Subthalamic nucleus and Parkinson's disease 339–340
Successful Scientific Writing: A Step-by-Step Guide for the Medical and Biological Sciences 202 (BR)
Sulphenic acid and NMDA receptors 188
Sulphonylurea receptor 273–274, 275
Superoxide dismutase
gene, Cu^{2+}–Zn^{2+}, familial amyotrophic lateral sclerosis and 114

PEG- 230
Suprachiasmatic nucleus, melatonin receptors 100
Supraventricular arrhythmias, adenosine effects 141
Surgical treatments in Parkinson's disease 339–340
Sympathetic vascular control, neuropeptide Y_1 receptors and 302–304
Synapse, *see* Neurotransmission; Neurotransmitters; Postsynaptic neurones; Presynaptic neurones

T
T-cell apoptosis, therapeutic induction 439–440
Tachycardia, adenosine effects 141
Tachykinin receptor antagonists and allergic airway disease 255–259
Tacrine 156
TBC11251 178, 179, 180
Teaching, *see* Pharmacology education/training
Terodiline, detrusor contractility reduced by 163
Tetrahydrobiopterin as cofactor in neuronal NO synthase 205
4,5,6,7-Tetrahydroisoxazole[4,5-*c*]pyridin-3-ol (THIP)
as $GABA_C$ antagonist 321, 322
structure 322
The Year's Drug News. Therapeutic Targets 203 (BR)
Theophylline
adenosine receptors and 108, 111–112, 369
seizures and chronic effects of 111–112
Thimet oligopeptidase 291
Thrombin
non-catalytic actions 5
receptor
protease-activated 4–5, 5
protease-activated receptor related to 5
Thrombolytics in stroke therapy 229, 231
Timmerman, Henk 127
TiPS
200th issue, celebration 122
Advisory Editorial Board 124–128
new members 7
past members 128
on identity 121
most cited articles up to 1994 123
TiPS/TiNS lecture, tyrosine hydroxylase and neuropsychiatric disorders 129–135
Tissue plasminogen activator, *see* Plasminogen activator
7TM domain receptors, *see* Transmembrane domain receptors
Tolerance liability with benzodiazepines 196
lack, with imidazenil 198
Toxicity (poisoning)
drug 317–318
mushrooms 173 (BR)
neurological, fluorinated pyrimidines 106 (L), 107 (L)
Toxicology
Annual Review of Pharmacology and (Vol. 36) 299 (BR)
Lommis's essentials of 203 (BR)
Training, *see* Pharmacology education/training
Transcription factors, glucocorticoid/mineralocorticoid receptor heterodimers interacting with other 147–148
Transmembrane domain (receptors)
of presenilin 390–393
seven, *see* Seven transmembrane domain receptors
Transmitters, *see* Neurotransmission; Neurotransmitters
Transporters with agonist-gated channels 308
Trauma, ubiquitin-dependent proteolysis in skeletal muscle 224–225
Trials, clinical, clinical pharmacologists' roles 46
Triazolam, cognition deficits induced by 198–199
Trichloroethanol and $5\text{-}HT_3$ receptors 95–97, 98
Tricyclic antidepressants in incontinence 163
Tropomyosin and actin–myosin interactions 286
Trypsin and insulin receptors 4
Tumour necrosis factor-α and ubiquitin system 225
Tumour necrosis factor receptor-1, p55 438–439
Tyrosine hydroxylase 129–135
neuropsychiatric disorders and 132–134
structure and diversity 129–130
trans-synaptic long-term activation 130–131

U
U74006F 230
Ubiquitin-dependent proteolysis in skeletal muscle 223–226
Undergraduate education, *see* Pharmacology education
Understanding Medications: What the Label Doesn't Tell You 173 (BR)
Uracil, 5-fluorouracil competing for β-alanine with 107 (L)
Urethral sphincter
contraction 161
control 161, 162
failure 163
drugs acting on 164, 165
innervation 162
Urinary bladder, *see* Bladder
USA, pharmacology education, *see* Pharmacology education

V
Vaccines, recombinant 450, 452
Vasculature
adenosine A_2 antagonist effects 370
adipose tissue, *in situ* microdialysis in assessment of response 309–313
endothelial NO synthase, stroke and 232
smooth muscle, leukotriene receptors and 343–344
sympathetic control, neuropeptide Y_1 receptors and 302–304
see also Cardiovascular system
Vasoconstriction, sympathetic, neuropeptide Y and 302–304
Ventral tegmental area
fluoxetine and the dopamine neurotransmitter system in 400
morphine addiction and 410, 411, 412
Ventricular automaticity, excitatory actions of adenosine 141–144
Vesicular acetyltransferase transporter gene 132
Vestibular nucleus 421–427
Vestibulo–ocular reflex system 421–427
Virally-encoded chemokine receptors 211
Voltage-gated ion channel blockers in stroke therapy 229, 231

W
Wang, Zhen-Gang 127
WHO Model Prescribing Information. Drugs used in Parasitic Diseases 175 (BR)
William Harvey Research Institute, 10th Anniversary 271
Writing, scientific 202
from home, freelance medical 64–65

X
Xanthines and adenosine receptors 108–113, 367, 369
see also specific xanthines
Xenopus oocytes, NR1 subunit of NMDA receptor forming functional channels in 348–349

Y
Yeast phospholipase D, structure 183–185

Z
ZD6169 163
Zinc and GABA-activated Cl^- current 322
ZM241385 368, 370

Books Reviewed Index

B

Benjamin, D. R., *Mushrooms: Poisons and Panaceas* 173

Bowman, W. C., Fitzgerald, J. D. and Taylor, J. B., eds, *Emerging Drugs. The Prospect for Improved Medicines Annual Executive Briefing, Vol. 1, 1996* 337

Burger, A., *Understanding Medications: What the Label Doesn't Tell You* 173

C

Cho, A. K., ed., *Annual Review of Pharmacology and Toxicology, Vol. 36 1996* 299

Claude Cohen, N., ed., *Guidebook on Molecular Modelling in Drug Design* 463

Coggins, C. H., ed., *Annual Review of Medicine: Selected Topics in the Clinical Sciences, Vol. 45* 270

Cohen, A. and Posner, J., eds, *A Guide to Clinical Drug Research* 463

D

Dale, M. M., Dickenson, A. H. and Haylett, D. G., *Companion to Pharmacology. A Study Guide For Self-assessment and Revision* 174

G

Greenwood, D., ed., *Antimicrobial Chemotherapy, 3rd edn* 28

H

Hoffman, J. F., ed., *Annual Review of Physiology, Vol. 58* 269

K

Kendall, D. A. and Hill, S. J., eds, *Signal Transduction Protocols* 201

L

Lieberman, H. A., Reiger, M. M. and Banker, G. S., eds, *Pharmaceutical Dosage Forms: Disperse Systems, 2nd edn, Vols 1 and 2* 382

Loomis, T. E. and Wallace Haynes, A., *Loomis's Essentials of Toxicology, 4th edn* 203

M

Matthews, J. R., Bowen, J. M. and Matthews, R. W., *Successful Scientific Writing: A Step-by-step Guide for the Biological and Medical Sciences* 202

O

Ortiz de Montellano, P. R., ed., *Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn* 174

P

Pertwee, R., ed., *Cannabinoid Receptors* 201

Prous, J. R., ed., *The Year's Drug News. Therapeutic Targets, 1995 edn* 203

T

Theoharides, T. C., *Essentials of Pharmacology, 2nd edn* 203

Tseng, L. F., ed., *The Pharmacology of Opioid Peptides* 234

W

van de Waterbeemd, H., ed., *Chemometric Methods in Molecular Design* 28

Just the tip of the iceberg...

http:
//www.
elsevier.com/
locate/tto

TECHNICAL
TIPS ONLINE

http://www.elsevier.com/locate/tto
In Europe http://www.elsevier.nl/locate/tto

...log-on today and search the depths.

NEW from Elsevier Trends Journals

Technical Tips Online - a database of techniques information for the life scientist.

http://www.elsevier.com/locate/tto

In Europe http://www.elsevier.nl/locate/tto

TECHNICAL
TIPS ONLINE

E L S E V I E R T R E N D S J O U R N A L S

AMERICAS: Elsevier Science, Regional Sales Office, Customer Support Department, 655 Avenue of the Americas, New York, NY 10010, USA Tel: +1 (212) 633 3730 Fax: +1 (212) 633 3680 E-mail: usinfo-f@elsevier.com EUROPE/ROW: Elsevier Science, Regional Sales Office, Customer Support Department, PO Box 211, 1000 AE Amsterdam, The Netherlands Tel: +31 (20) 485 3757 Fax: +31 (20) 485 3432 E-mail: nlinfo-f@elsevier.nl SINGAPORE (ASIA PACIFIC EXCEPT JAPAN): Elsevier Science, Regional Sales Office, Customer Support Department, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192 Tel: +65 336 9338 Fax: +65 337 2230 E-mail: asiainfo@elsevier.com.sg JAPAN: Elsevier Science, Regional Sales Office, Customer Support Department, 9–15 Higashi-Azabu, 1-chome, Minato-ku, Tokyo 106, Japan. Tel: +81 (3) 5561 5033 Fax: +81 (3) 5561 5047 E-mail: kyf04035@niftyserve.or.jp

ELSEVIER TRENDS JOURNALS